Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML)in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY).

Trial Profile

Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML)in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms SIMPLICITY
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Jun 2018 Preliminary results (as of 7 Sep 2017; n=1240) presented at the 23rd Congress of the European Haematology Association
    • 12 Dec 2017 Results (as of 3 Mar 2017, n=1242) assessing the factors associated with achievement of complete CyR (CCyR) and major MR (MMR), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Nov 2017 According to a Bristol-Myers Squibb media release, data of the trial will be present at the 59th Annual Meeting & Exposition of the American Society of Hematology 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top